<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594397</url>
  </required_header>
  <id_info>
    <org_study_id>2014CB543102-2</org_study_id>
    <nct_id>NCT02594397</nct_id>
  </id_info>
  <brief_title>Acupuncture for Diabetic Gastroparalysis: a Randomized Controlled Trial</brief_title>
  <acronym>ADG-RCT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the different combination of acupoints have&#xD;
      different effect on diabetic gastroparalysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the score of GCSI</measure>
    <time_frame>4 weeks</time_frame>
    <description>GCSI means gastroparesis cardinal symptom index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying time</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gastrin concentrations</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>motilin concentrations</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Diabetes Complications</condition>
  <arm_group>
    <arm_group_label>acupoints combination 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acupoints comination 1 includes the specific acupoint ST36 (Zusanli) and a local acupoint CV12 (Zhongwan).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acupoints combination 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>acupoints comination 2 includes the specific acupoint ST36 (Zusanli) and a distal acupoint PC6(Neiguan).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham acupoints combination</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham acupoints combination includes the specific acupoint ST36 (Zusanli) and a sham acupoint.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>acupoints combination 1</intervention_name>
    <arm_group_label>acupoints combination 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>acupoints combination 2</intervention_name>
    <arm_group_label>acupoints combination 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham acupoints combination</intervention_name>
    <arm_group_label>sham acupoints combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  individuals who meet the diagnostic criteria of diabetes gastric paralysis.&#xD;
&#xD;
          -  individuals between the ages of 18 and 60 years.&#xD;
&#xD;
          -  individuals who meet blood glucose control standards: Fasting plasma glucose (FPG) ≤7.&#xD;
             8mmol/L; 2 hours plasma glucose (2hPG)≤13.6mmol/L.&#xD;
&#xD;
          -  individuals who suffered for more than 3 years.&#xD;
&#xD;
          -  individuals who treated with diet control or exercise or using hypoglycemic drug&#xD;
             (except for α-glucosidase Inhibitor) on the basis of diet or exercise therapy and the&#xD;
             dose stability must be last at least 3 months.&#xD;
&#xD;
          -  individuals who receive no other treatments in the first 3 months.&#xD;
&#xD;
          -  women who is at the age of childbearing age and take contraceptive measures.&#xD;
&#xD;
          -  individuals who voluntarily agree with a study protocol and sign a written informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  individuals who have reflux esophagitis;&#xD;
&#xD;
          -  individuals who have gastroparesis after surgery;&#xD;
&#xD;
          -  individuals who have acute complications with ketoacidosis and nonketotic hyperosmolar&#xD;
             coma;&#xD;
&#xD;
          -  individuals who have Acute cardiovascular and cerebrovascular diseases or Severe&#xD;
             trauma or surgery, severe infection. Or who are pregnant or breastfeeding;&#xD;
&#xD;
          -  individuals who have a history disease of myocardial infarction, acute coronary&#xD;
             syndrome or coronary revascularization;&#xD;
&#xD;
          -  individuals who have serious hepatobiliary disease, or AST and/or ALT 2 times greater&#xD;
             than the upper limit of normal patients;&#xD;
&#xD;
          -  individuals with kidney damage, and serum creatinine exceeds 140umol/L;&#xD;
&#xD;
          -  individuals who have obvious blood system diseases (Any one of which can not be caught&#xD;
             in line: Hb: male&lt;110g/L, women&lt;100g/L,WBC&lt;3.5×109/L,PLT&lt;80×109/L).&#xD;
&#xD;
          -  individuals who have a problem of blood press:SBP≥180mmHg,DPB≥100mmHg;&#xD;
&#xD;
          -  individuals who have cancer or other serious progressive wasting disease, and easy to&#xD;
             infection and bleeding;&#xD;
&#xD;
          -  individuals who have peptic ulcer or other organic disease confirmed by&#xD;
             esophagogastroduodenoscopy;&#xD;
&#xD;
          -  individuals unwilling to meet the testing and exacerbations,or have serious&#xD;
             complications in the test;&#xD;
&#xD;
          -  individuals who have taking α-glucosidase inhibitor drug in the past four weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zenghui Yue, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Hunan University of Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mailan Liu, Dr.</last_name>
    <phone>86-731-88458187</phone>
    <email>445007305@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping Li</last_name>
    <email>472198992@qq.com</email>
  </overall_contact_backup>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>October 31, 2015</study_first_submitted>
  <study_first_submitted_qc>October 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>October 31, 2015</last_update_submitted>
  <last_update_submitted_qc>October 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

